CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE . JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES.. SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .
13 febrero 2009
11 febrero 2009
Aplidin . Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs.
Publicado en la :
Current Medicinal Chemistry
Volume 16, Number 6, 2009
Current Medicinal Chemistry
Volume 16, Number 6, 2009
10 febrero 2009
Fase I-II A Placebo-Controlled Study Evaluating the Potential Effects of Trabectedin on the Heart in Patients With Advanced Cancer .
Ensayo Clinico de la Mano de J & J ... actualizado :
Study ID Numbers: CR014917
Study First Received: November 4, 2008
Last Updated: January 29, 2009
ClinicalTrials.gov Identifier: NCT00786838 [history]
Health Authority: United States: Food and Drug Administration
Study ID Numbers: CR014917
Study First Received: November 4, 2008
Last Updated: January 29, 2009
ClinicalTrials.gov Identifier: NCT00786838 [history]
Health Authority: United States: Food and Drug Administration
07 febrero 2009
Alzheimer, ¿una diabetes cerebral? .
La forma más común de demencia, la enfermedad de Alzheimer, podría estar muy relacionada a otro trastorno muy común en la vejez: la diabetes tipo 2. ...
06 febrero 2009
Pharma Mar consigue la Patente para varios compuestos obtenidos de la esponja de la familia Theonellidae .
Antitumour Compounds
Publication number: US2009030068 (A1)
Publication date: 2009-01-29
Inventor(s): MARTIN LOPEZ MA JESUS [ES]; REYES BENITEZ JOSE FERNANDO [ES]; FERNANDEZ RODRIGUEZ ROGELIO [ES]; FRANCESCH SOLLOSO ANDRES [ES]; CUEVAS MARCHANTE MARIA DEL CARMEN [ES]; COELLO MOLINERO LAURA [ES]
Applicant(s): PHARMA MAR SA [ES]
Classification:
- international: A61K31/335; A61P35/00; C07D323/00; A61K31/335; A61P35/00; C07D323/00
- European: C07D493/18; C07D493/18
Application number: US20060097212 20061214
Priority number(s): ES20050003092 20051215; WO2006ES00687 20061214
View INPADOC patent family
View list of citing documents
Abstract of US 2009030068 (A1)
The invention relates to novel antitumor compounds of general formula as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.
Publication number: US2009030068 (A1)
Publication date: 2009-01-29
Inventor(s): MARTIN LOPEZ MA JESUS [ES]; REYES BENITEZ JOSE FERNANDO [ES]; FERNANDEZ RODRIGUEZ ROGELIO [ES]; FRANCESCH SOLLOSO ANDRES [ES]; CUEVAS MARCHANTE MARIA DEL CARMEN [ES]; COELLO MOLINERO LAURA [ES]
Applicant(s): PHARMA MAR SA [ES]
Classification:
- international: A61K31/335; A61P35/00; C07D323/00; A61K31/335; A61P35/00; C07D323/00
- European: C07D493/18; C07D493/18
Application number: US20060097212 20061214
Priority number(s): ES20050003092 20051215; WO2006ES00687 20061214
View INPADOC patent family
View list of citing documents
Abstract of US 2009030068 (A1)
The invention relates to novel antitumor compounds of general formula as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.
04 febrero 2009
Sociedad Española de Oncología Médica (SEOM) crea la primera TV de una sociedad Medica . Pharma Mar junto a otras 11 Farmas Oncolgicas lo Financian .
*.- Para ver el canal TV SEOM ... pikar en el titular .
*.- Más info : http://www.elsemanaldigital.com/articulos.asp?idarticulo=92585
Yondelis en Combinacion con Capecitabine . Nueva Patente conseguida .
COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO-DRUGS FOR THE TREATMENT OF CANCER
Publication number: HR20080598 (T3)
Publication date: 2009-01-31
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: HR20080000598T 20081202
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115
Abstract not available for HR 20080598 (T3)
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m<2> for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
Publication number: HR20080598 (T3)
Publication date: 2009-01-31
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: HR20080000598T 20081202
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115
Abstract not available for HR 20080598 (T3)
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m<2> for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
Yondelis activo contra el Cancer de Melanoma . EPAR EMEA pag . 4 .
Melanoma , esta indicacion consta en la Propia EMEA .... en el EPAR de la aprobación del Yondelis STS .... ver pagina 4 .
Trabectedin binds to the minor groove of DNA, bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.
El gran problema del cáncer es que falta traducir lo que sabemos a fármacos .
María Blasco es directora del Programa de Oncología Molecular del Centro Nacional de Investigaciones Oncológicas (CNIO) y ha conseguido que su nombre destaque en letras mayúsculas en el mundo de la ciencia ...
Suscribirse a:
Entradas (Atom)